| Literature DB >> 31116423 |
Wafik S El-Deiry1, Richard M Goldberg2, Heinz-Josef Lenz3, Anthony F Shields4, Geoffrey T Gibney5, Antoinette R Tan6, Jubilee Brown7, Burton Eisenberg8,9, Elisabeth I Heath10, Surasak Phuphanich11, Edward Kim12, Andrew J Brenner13, John L Marshall14.
Abstract
The world of molecular profiling has undergone revolutionary changes over the last few years as knowledge, technology, and even standard clinical practice have evolved. Broad molecular profiling is now nearly essential for all patients with metastatic solid tumors. New agents have been approved based on molecular testing instead of tumor site of origin. Molecular profiling methodologies have likewise changed such that tests that were performed on patients a few years ago are no longer complete and possibly inaccurate today. As with all rapid change, medical providers can quickly fall behind or struggle to find up-to-date sources to ensure he or she provides optimum care. In this review, the authors provide the current state of the art for molecular profiling/precision medicine, practice standards, and a view into the future ahead.Entities:
Keywords: biomarkers; cancer; drug target; gene expression profiling; molecular profiling; molecular-targeted therapy; mutation; precision medicine; sequence analysis
Mesh：
Substances：
Year: 2019 PMID： 31116423 PMCID： PMC6767457 DOI： 10.3322/caac.21560
Source DB: PubMed Journal: CA Cancer J Clin ISSN： 0007-9235 Impact factor: 508.702